Key Points
- Insider John Fesko sold 17,806 Natera shares on Jan. 20 at an average price of $234.74 for about $4.18M, trimming his stake by 9.11% to 177,591 shares valued at roughly $41.69M.
- Multiple senior insiders also executed large, clustered sales — CEO Steven Leonard Chapman sold 71,932 shares (reducing his stake ~24.9%) and CFO Michael Brophy sold 23,948 and 37,175 shares — actions that could negatively affect near‑term market sentiment.
- Natera posted revenue of $592.2M (up 34.7%) that beat estimates but missed on EPS (−$0.64 vs. −$0.39), has negative margins, a market cap of $33.6B, and an average analyst rating of Moderate Buy with a $245.50 target.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 293 shares of the firm's stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $68,855.00. Following the completion of the transaction, the insider owned 144,699 shares of the company's stock, valued at $34,004,265. This trade represents a 0.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Solomon Moshkevich also recently made the following trade(s):
- On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
- On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
- On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
- On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.
- On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total transaction of $595,800.00.
- On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $229,369.08.
- On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $193,858.56.
Natera Price Performance
Shares of NASDAQ NTRA opened at $242.91 on Friday. The stock has a market capitalization of $33.60 billion, a price-to-earnings ratio of -106.07 and a beta of 1.62. The firm's 50 day simple moving average is $233.44 and its 200-day simple moving average is $190.60. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm's quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.26) EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.
Trending Headlines about Natera
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology, strengthening clinical credibility for a higher‑value oncology product that could support future revenue/coverage expansion. Clinical validation article
- Positive Sentiment: Multiple sell‑side analysts have raised price targets (examples: Barclays, JPMorgan, Guggenheim) and the consensus remains a "Moderate Buy" with a MarketBeat implied target around $245.50 — bullish support for the stock's medium‑term outlook. Analyst coverage summary
- Neutral Sentiment: Institutional ownership is extremely high (~99.9%), and recent quarter revenue growth was strong (revenue up ~34.7% YoY), but profitability remains negative — factors that can both support and cap near‑term moves depending on execution and sentiment.
- Negative Sentiment: CEO Steven Chapman executed a large sale on Jan. 20 (71,932 shares, ~$16.9M at ~$234.74) and additional smaller sales on Jan. 21 — a material reduction in his stake that markets often interpret as negative signal. CEO Form 4
- Negative Sentiment: CFO Michael Burkes Brophy sold large blocks across Jan. 20–21 (23,948 and 37,175 shares), cutting his ownership materially — another significant insider liquidation that increases perceived supply and can pressure the stock. CFO Form 4
- Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold sizable positions (tens of thousands of shares combined) on Jan. 20–21 — the clustered timing of multiple insider sales magnifies negative investor perception. Insider Form 4 example
Wall Street Analyst Weigh In
NTRA has been the topic of a number of research reports. Piper Sandler raised their target price on shares of Natera from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 11th. Stephens boosted their price objective on Natera from $197.00 to $235.00 and gave the stock an "overweight" rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Natera in a research note on Wednesday, October 8th. BTIG Research boosted their price target on shares of Natera from $230.00 to $260.00 and gave the company a "buy" rating in a research report on Friday, December 5th. Finally, Morgan Stanley upped their price objective on shares of Natera from $220.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $245.50.
Read Our Latest Report on Natera
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC raised its holdings in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock valued at $221,000 after buying an additional 96 shares during the period. NewEdge Advisors LLC increased its stake in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth lifted its position in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock worth $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Natera during the second quarter worth about $298,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Natera by 46.4% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 28,323 shares of the medical research company's stock valued at $4,582,000 after purchasing an additional 8,977 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
